Get the Stockscreener App
34.42
0.12%
0.04
Pre-market:
33.51
-0.91
-2.64%
Agios Pharmaceuticals Inc Stock (AGIO) Latest News
Biliary Tract Cancer Pipeline 2024: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Agios Pharma, Servier Pharma, Merck Sharp & Dohme, AstraZeneca, Taiho Onco - Barchart
Q4 Earnings Alert: Agios Pharmaceuticals Sets Critical Financial Update for Rare Disease Pipeline - StockTitan
Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025 - The Manila Times
Agios Pharmaceuticals to Host Conference Call for 2024 Financial Results on February 13, 2025 - Nasdaq
Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025 - GlobeNewswire Inc.
Agios Pharmaceuticals principal accounting officer sells shares for $78,134 - MSN
Short Interest in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Expands By 8.0% - MarketBeat
Brokerages Set Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Target Price at $56.33 - MarketBeat
Alpha Thalassemia Pipeline 2024: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Genmedicn Biopharma Ltd., Bristol-Myers Squibb, Agios Pharma - The Globe and Mail
Alpha Thalassemia Pipeline 2024: MOA and ROA Insights, Clinical - openPR
Beta Thalassemia Market on Track for Major Expansion by 2034, According to DelveInsight | Agios Pharma, Vertex Pharma, Pharmacosmos, Editas Medicine, HemaQuest Pharma, Acceleron Pharma, Bristol-Myers - Barchart
Beta Thalassemia Market on Track for Major Expansion by 2034, - openPR
Short Interest in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Increases By 8.0% - MarketBeat
J.P. Morgan Notebook: Priorities For The Year Ahead - News & Insights
Alpha Thalassemia Pipeline 2024: Clinical Trials Assessment, - openPR
Agios Pharmaceuticals: Considering Risk/Reward Ahead Of FDA Decision (NASDAQ:AGIO) - Seeking Alpha
Why Agios Pharmaceuticals (AGIO) Is the Top Small Cap Stock to Buy with the Highest Upside Potential - Insider Monkey
Agios Pharmaceuticals announces key 2025 milestones, catalysts through 2026 - MSN
Agios Pharma Sets Milestones for Rare Disease Growth - TipRanks
Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio - The Manila Times
Agios' PYRUKYND Gets FDA Review for Thalassemia Treatment, Major Pipeline Progress for 2025 - StockTitan
Top 10 Small Cap Stocks to Buy with the Highest Upside Potential - Insider Monkey
The week in pharma: action, reaction and insight – week to January 10 - The Pharma Letter
Agios' supplemental new drug application for its thalassemia treatment gets FDA nod - MSN
Agios Pharmaceuticals (AGIO-Q) QuotePress Release - The Globe and Mail
FDA Accepts Agios' sNDA for Pyrukynd in Thalassemia - MSN
Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price Down 7.5%Should You Sell? - MarketBeat
FDA accepts Agios' sNDA for thalassemia treatment PYRUKYND By Investing.com - Investing.com South Africa
Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer – Company Announcement - Financial Times
FDA accepts Agios' sNDA for thalassemia treatment PYRUKYND - Investing.com India
FDA Accepts Agios' Supplemental New Drug Application for PYRUKYND® (mitapivat) in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia - The Manila Times
FDA Accepts Agios' PYRUKYND® Application for Thalassemia Treatment Expansion - StockTitan
Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer - Yahoo Finance
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Insider Sells 2,804 Shares - MarketBeat
Agios Pharmaceuticals executive sells shares worth $90,232 By Investing.com - Investing.com Canada
Agios Pharmaceuticals executive sells shares worth $90,232 - Investing.com
FDA liver injury warning label for Agios' Pyrukynd - The Pharma Letter
FDA approves label update for Agios's PYRUKYND By Investing.com - Investing.com Australia
Agios Pharmaceuticals (NASDAQ:AGIO) Sees Strong Trading VolumeWhat's Next? - MarketBeat
FDA approves label update for Agios’s PYRUKYND By Investing.com - Investing.com Nigeria
FDA approves label update for Agios's PYRUKYND - Investing.com India
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):